Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ardelyx, Inc. stock logo
ARDX
Ardelyx
$4.60
+2.2%
$3.90
$3.21
$7.18
$1.08B0.64.42 million shs3.89 million shs
BioSpecifics Technologies Corp. stock logo
BSTC
BioSpecifics Technologies
$88.53
$88.47
$42.00
$89.15
$650.25M0.2461,105 shsN/A
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
$0.70
-7.7%
$0.53
$0.32
$2.07
$42.44M2.12848,835 shs376,000 shs
Morphic Holding, Inc. stock logo
MORF
Morphic
$56.99
$56.76
$19.34
$57.00
$2.85B1.491.27 million shs400 shs
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$3.44
-0.6%
$3.40
$2.23
$4.13
$171.72M1.29412,085 shs301,232 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ardelyx, Inc. stock logo
ARDX
Ardelyx
+2.22%0.00%+25.68%-4.56%-25.93%
BioSpecifics Technologies Corp. stock logo
BSTC
BioSpecifics Technologies
0.00%0.00%0.00%0.00%0.00%
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
0.00%0.00%0.00%0.00%0.00%
Morphic Holding, Inc. stock logo
MORF
Morphic
0.00%0.00%0.00%0.00%+1.79%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
-0.58%-4.44%-0.29%+20.28%-12.91%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ardelyx, Inc. stock logo
ARDX
Ardelyx
4.0978 of 5 stars
3.51.00.04.42.62.50.6
BioSpecifics Technologies Corp. stock logo
BSTC
BioSpecifics Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Morphic Holding, Inc. stock logo
MORF
Morphic
0.9833 of 5 stars
1.00.00.04.80.03.30.0
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
4.2202 of 5 stars
3.52.00.00.02.64.23.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ardelyx, Inc. stock logo
ARDX
Ardelyx
3.00
Buy$10.89136.71% Upside
BioSpecifics Technologies Corp. stock logo
BSTC
BioSpecifics Technologies
0.00
N/AN/AN/A
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
0.00
N/AN/AN/A
Morphic Holding, Inc. stock logo
MORF
Morphic
2.00
Hold$57.000.02% Upside
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
3.00
Buy$7.00103.49% Upside

Current Analyst Ratings Breakdown

Latest PBYI, BSTC, ARDX, MORF, and MGTA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/18/2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$10.00
5/2/2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$11.00 ➝ $10.00
5/2/2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Outperform$11.00
(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ardelyx, Inc. stock logo
ARDX
Ardelyx
$333.61M3.30N/AN/A$0.73 per share6.30
BioSpecifics Technologies Corp. stock logo
BSTC
BioSpecifics Technologies
$38.19M17.03$3.38 per share26.18$18.42 per share4.81
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
N/AN/AN/AN/A$1.23 per shareN/A
Morphic Holding, Inc. stock logo
MORF
Morphic
$520K5,490.11N/AN/A$12.31 per share4.63
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$230.50M0.74$0.85 per share4.06$1.88 per share1.83
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ardelyx, Inc. stock logo
ARDX
Ardelyx
-$39.14M-$0.22N/A14.84N/A-14.86%-34.45%-13.81%7/30/2025 (Estimated)
BioSpecifics Technologies Corp. stock logo
BSTC
BioSpecifics Technologies
$24.47M$3.3337.5117.60N/A47.43%14.81%14.46%N/A
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
-$76.46MN/A0.00N/AN/A-70.88%-57.27%N/A
Morphic Holding, Inc. stock logo
MORF
Morphic
-$152.10M-$3.50N/AN/AN/AN/A-26.62%-25.74%N/A
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$30.28M$0.774.479.05N/A16.37%49.35%18.25%7/30/2025 (Estimated)

Latest PBYI, BSTC, ARDX, MORF, and MGTA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
-$0.12N/AN/AN/AN/AN/A
8/7/2025Q2 2025
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$0.11N/AN/AN/A$52.00 millionN/A
5/1/2025Q1 2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
-$0.10-$0.17-$0.07-$0.17$79.40 million$74.11 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ardelyx, Inc. stock logo
ARDX
Ardelyx
N/AN/AN/AN/AN/A
BioSpecifics Technologies Corp. stock logo
BSTC
BioSpecifics Technologies
N/AN/AN/AN/AN/A
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
N/AN/AN/AN/AN/A
Morphic Holding, Inc. stock logo
MORF
Morphic
N/AN/AN/AN/AN/A
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ardelyx, Inc. stock logo
ARDX
Ardelyx
1.04
4.12
3.81
BioSpecifics Technologies Corp. stock logo
BSTC
BioSpecifics Technologies
N/A
66.24
66.24
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
N/A
19.49
19.49
Morphic Holding, Inc. stock logo
MORF
Morphic
N/A
24.13
24.13
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
0.11
1.53
1.43

Institutional Ownership

CompanyInstitutional Ownership
Ardelyx, Inc. stock logo
ARDX
Ardelyx
58.92%
BioSpecifics Technologies Corp. stock logo
BSTC
BioSpecifics Technologies
60.34%
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
47.53%
Morphic Holding, Inc. stock logo
MORF
Morphic
94.25%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
61.29%

Insider Ownership

CompanyInsider Ownership
Ardelyx, Inc. stock logo
ARDX
Ardelyx
4.80%
BioSpecifics Technologies Corp. stock logo
BSTC
BioSpecifics Technologies
15.70%
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
15.18%
Morphic Holding, Inc. stock logo
MORF
Morphic
25.60%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
23.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ardelyx, Inc. stock logo
ARDX
Ardelyx
90239.26 million227.77 millionOptionable
BioSpecifics Technologies Corp. stock logo
BSTC
BioSpecifics Technologies
77.35 millionN/ANot Optionable
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
6760.67 million51.46 millionNot Optionable
Morphic Holding, Inc. stock logo
MORF
Morphic
10050.09 million37.27 millionOptionable
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
20049.63 million38.07 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ardelyx stock logo

Ardelyx NASDAQ:ARDX

$4.60 +0.10 (+2.22%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$4.62 +0.02 (+0.46%)
As of 07:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

BioSpecifics Technologies stock logo

BioSpecifics Technologies NASDAQ:BSTC

BioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware.

Magenta Therapeutics stock logo

Magenta Therapeutics NASDAQ:MGTA

Magenta Therapeutics, Inc., a biotechnology company focus on improving stem cell transplantation. Its product candidates are designed to bring the curative power of stem cell transplant to patients with blood cancers, genetic diseases, and autoimmune diseases. The company's product portfolio includes MGTA-117, an anti-CD117 antibody conjugated to an amanitin payload that targets hematopoietic stem cells (HSCs) and leukemia cells; and MGTA-45, an anti-human CD45 antibody conjugated to a DNA-interacting payload for HSCs, leukemia cells, and immune cells. In addition, it focus on development of ADC-based conditioning program that targets a receptor of T cells; and novel conditioning and translation stem cell sciences, as well as develops cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. In addition, the company has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. Magenta Therapeutics, Inc. was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Morphic stock logo

Morphic NASDAQ:MORF

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Puma Biotechnology stock logo

Puma Biotechnology NASDAQ:PBYI

$3.44 -0.02 (-0.58%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$3.51 +0.07 (+2.03%)
As of 07:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.